These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32554470)

  • 1. New emerging targets in cancer immunotherapy: the role of VISTA.
    Tagliamento M; Bironzo P; Novello S
    ESMO Open; 2020 Jun; 4(Suppl 3):e000683. PubMed ID: 32554470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy.
    Im E; Sim DY; Lee HJ; Park JE; Park WY; Ko S; Kim B; Shim BS; Kim SH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):1066-1075. PubMed ID: 34428551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VISTA: A Promising Target for Cancer Immunotherapy?
    Tagliamento M; Agostinetto E; Borea R; Brandão M; Poggio F; Addeo A; Lambertini M
    Immunotargets Ther; 2021; 10():185-200. PubMed ID: 34189130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway.
    Zheng S; Zhang K; Zhang X; Xiao Y; Wang T; Jiang S
    J Med Chem; 2022 Sep; 65(18):11900-11912. PubMed ID: 36083840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
    Liu J; Yuan Y; Chen W; Putra J; Suriawinata AA; Schenk AD; Miller HE; Guleria I; Barth RJ; Huang YH; Wang L
    Proc Natl Acad Sci U S A; 2015 May; 112(21):6682-7. PubMed ID: 25964334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
    Mortezaee K; Majidpoor J; Najafi S
    Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VISTA is an immune checkpoint molecule for human T cells.
    Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
    Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer.
    Cao Y; Yu K; Zhang Z; Gu Y; Gu Y; Li W; Zhang W; Shen Z; Xu J; Qin J
    Clin Transl Med; 2024 Feb; 14(2):e1578. PubMed ID: 38356419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VISTA expressed in tumour cells regulates T cell function.
    Mulati K; Hamanishi J; Matsumura N; Chamoto K; Mise N; Abiko K; Baba T; Yamaguchi K; Horikawa N; Murakami R; Taki M; Budiman K; Zeng X; Hosoe Y; Azuma M; Konishi I; Mandai M
    Br J Cancer; 2019 Jan; 120(1):115-127. PubMed ID: 30382166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
    Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
    Front Immunol; 2019; 10():1638. PubMed ID: 31379838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VISTA expression and patient selection for immune-based anticancer therapy.
    Martin AS; Molloy M; Ugolkov A; von Roemeling RW; Noelle RJ; Lewis LD; Johnson M; Radvanyi L; Martell RE
    Front Immunol; 2023; 14():1086102. PubMed ID: 36891296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
    Kok VC
    Front Oncol; 2020; 10():268. PubMed ID: 32185135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of immune checkpoint inhibitors].
    Kitano S
    Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patients' response to cancer immunotherapy.
    Omar HA; Tolba MF
    Crit Rev Oncol Hematol; 2019 Mar; 135():21-29. PubMed ID: 30819443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Assessment of Immune Checkpoint Regulator VISTA on Tumor-Associated Immune Cells and Platelet-to-Lymphocyte Ratio Identifies Advanced Germ Cell Tumors with Higher Risk of Unfavorable Outcomes.
    Pęksa R; Kunc M; Popęda M; Piątek M; Bieńkowski M; Żok J; Starzyńska A; Perdyan A; Sowa M; Duchnowska R; Biernat W
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33916925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA.
    Li TT; Jiang JW; Qie CX; Xuan CX; Hu XL; Liu WM; Chen WT; Liu J
    BMC Immunol; 2021 Aug; 22(1):55. PubMed ID: 34380434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.
    Wang G; Tai R; Wu Y; Yang S; Wang J; Yu X; Lei L; Shan Z; Li N
    Cytokine Growth Factor Rev; 2020 Apr; 52():1-14. PubMed ID: 32057701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
    Yuan L; Tatineni J; Mahoney KM; Freeman GJ
    Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.